No Detail Found!

Fatty Liver Index and GGT/HDL-c Ratio in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease Treated with Life Style Modification or Vitamin E or Pentoxifylline

Author(s)
Chra Salahalddin Ahmed Department of Clinical Pharmacy, College of Pharmacy, University of Sulaimani, Sulaimaniyah, Iraq
Fenk Bakir Maarouf Author Designation:,,
Mohammed Omer Mohammed Raheem Branch of Clinical Sciences, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq
Heshu Sulaiman Rahman Branch of Basic Medical Sciences, College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq
Mohamed El-Kassas Department of Endemic Medicine, Faculty of Medicine, Capital University, Cairo, Egypt
Abstract
Background: Metabolic dysfunction associated steatotic liver disease (MASLD) is a common cause of chronic liver disease. It is becoming a major public health concern, with projections indicating a substantial increase in prevalence over the coming decades. Objectives: To evaluate the relationship of the Gamma Glutamyl transpeptidase (GGT) to high-density lipoprotein cholesterol (HDL-c) ratio and determine the fatty liver index (FLI) in patients with MASLD treated with pentoxifylline (PTX) and Vitamin E (VE). Patients and Methods: This randomized, single-blind, interventional study was conducted on 180 patients with MASLD in the Gastroenterology and Hepatology Teaching Hospital, Sulaimaniyah, Iraq, from January 2022 to June 2023. Patients were equally divided into three groups (n = 60 each): Group 1 received a placebo (control); Group 2 received VE; and Group 3 received PTX. Patients were received the treatments orally at a dose of 400 mg, twice daily for 6 months. Then, liver aminotransferase tests, haematological biomarkers, lipid profiles and FLI were measured before and after intervention. Results: The majority of patients were males (n = 96), with an age range of 20-40 years. All groups showed significant reductions in aminotransferase levels, lipid profile, high- sensitivity C-reactive protein (Hs-CRP), FLI, GGT/HDLc and GGT/body mass index (BMI) ratio after 6 months of treatments with either VE or PTX. Conclusions: PTX and more specifically, VE reduced FLI, GGT/HDL-c and GGT/BMI ratio. They also significantly improved hepatic aminotransferase levels, lipid profiles and Hs-CRP levels.
Publication Details
Page(s) 22-28
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 5, Year: 2026

Request the full text from PASTIC

Keywords
Life Style, Vitamin E, Pentoxifylline, Metabolic Associated Steatotic Liver Disease
References
Mejía-Guzmán J.E.,Metabolic-DysfunctionAssociated Steatotic Liver J.E. .2025 .Disease: Molecular Mechanisms, Clinical Implications and Emerging Therapeutic Strategies. International Journal of Molecular Sciences, 26 : .
Margini C.,Dufour J.F. .2016 .The Story of HCC in NAFLD: From Epidemiology, across Pathogenesis, to Prevention and Treatment. , 36 : 317-324.
Loomba R.,Sanyal A.J. .2013 .. The Global NAFLD Epidemic.” Nature Reviews Gastroenterology & Hepatology, 10 : 686-690.
Feng G. .2020 .Association between Ratio of γ-Glutamyl Transpeptidase to High-Density Lipoprotein Cholesterol and Prevalence of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Cross-Sectional Study. ” Annals of Translational Medicine, 8 : .
Tilg H.,Moschen A.R. .2010 .Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. ” Hepatology, 52 : 1836-1846.
Bołdys A. .2023 .Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. ” Medicina, 59 : .
Diehl A.M.,Day C. .2017 .. Pathogenesis and Treatment of Nonalcoholic Steatohepatitis.” New England Journal of Medicine, 377 : 2063-2072.
Khang A.R. .2019 .The Fatty Liver Index, a Simple and Useful Predictor of Metabolic Syndrome: Analysis of the Korea National Health and Nutrition Examination Survey 2010-. Metabolic Syndrome and Obesity: Targets and Therapy, : 181-190.
Fouda A. .2021 .A Randomized Controlled Trial Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxifylline on Egyptian Non-Alcoholic Steatohepatitis Patients.” European Review for Medical & Pharmacological Sciences. , 25 : .
Xing Y.,Diabetes Y. .2022 .Associations between GGT/HDL and MAFLD: A Cross-Sectional Study. Metabolic Syndrome and Obesity: Targets and Therapy, : 383-394.
Wang J. .2015 .ZJU Index: A Novel Model for Predicting Nonalcoholic Fatty Liver Disease in a Chinese Population. Scientific Reports, 5 : .
Li Q. .2022 .Gamma-Glutamyl Transferase to High-Density Lipoprotein Cholesterol Ratio Has a Non-Linear Association with Non-Alcoholic Fatty Liver Disease: A Secondary Prospective Cohort Study in Non-Obese Chinese Adults. , 9 : .
Cherubini A. .2024 .. Sexual Dimorphism of Metabolic Dysfunction-Associated Steatotic Liver Disease.” Trends in Molecular Medicine, : .
Jung H.S. .2019 .Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. American Journal of Gastroenterology, 114 : 453-463.
Ashraf S. . .An Open-Label Randomized Clinical Study to Compare the Effects of a Nutritional Supplement versus Vitamin E on Fibroscan Score in Nonalcoholic Steatohepatitis (NASH) Patients. Universal Journal of Public Health, 6(2018) : 56-62.
Saboori S. .2015 .Effect of Vitamin E Supplementation on Serum C-Reactive Protein Level: A Meta-Analysis of Randomized Controlled Trials. European Journal of Clinical Nutrition, 69 : 867-873.
Kumar R. .2020 .Association of High-Sensitivity C-Reactive Protein (hs-CRP) with Non-Alcoholic Fatty Liver Disease (NAFLD) in Asian Indians: A Cross-Sectional Study. ” Journal of Family Medicine and Primary Care, 9 : .
Debbabi M. .2016 .Protective Effects of α-Tocopherol, γ- Tocopherol and Oleic Acid, Three Compounds of Olive Oils and No Effect of Trolox, on 7-Ketocholesterol-Induced Mitochondrial and Peroxisomal Dysfunction in Microglial BV-2 Cells. International Journal of Molecular Sciences, 17 : .
Papatheodoridi M.,E. Cholongitas. M. .2018 .Diagnosis of NonAlcoholic Fatty Liver Disease (NAFLD): Current Concepts. ” Current Pharmaceutical Design, 24 : 4574-4586.
Derakhshandeh-Rishehri S.,Phospholipid-Vitamin E Complex S. .2020 .) on Liver Enzymes in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis of RCTs. Acta Endocrinologica (Bucharest), 16 : .
Hasegawa T. .2001 .Plasma Transforming Growth Factor-β1 Level and Efficacy of α-Tocopherol in Patients with NonAlcoholic Steatohepatitis: A Pilot Study. Alimentary Pharmacology & Therapeutics, 15 : 1667-1672.
0

Citations

0

Downloads

17

Views